{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"13"}],"units":"Participants"}],"description":"Toxicity assessed using NCI-CTC v. 3.0","groups":[{"description":"Phase I Weekly 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide","id":"OG000","title":"1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide"},{"description":"Phase I Weekly 1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide","id":"OG001","title":"1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide"},{"description":"Phase I Weekly 1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide","id":"OG002","title":"1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide"},{"description":"Phase I Weekly 1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide","id":"OG003","title":"1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide"},{"description":"Phase I Twice Weekly 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide","id":"OG004","title":"Dose Level 1- 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid"},{"description":"Phase I Twice Weekly 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide","id":"OG005","title":"Dose Level 2 - 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid"},{"description":"Phase I Twice Weekly 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide","id":"OG006","title":"Dose Level 3 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham"},{"description":"Phase I Twice Weekly 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide","id":"OG007","title":"Dose Level 4 - 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami"},{"description":"Phase I Twice Weekly 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide; Pegylated G-CSF","id":"OG008","title":"Dose Level 5 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham"},{"description":"Phase II Randomized Weekly bortezomib dosing schedule","id":"OG009","title":"Weekly Bortezomib Dosing Schedule"},{"description":"Phase II Randomized Twice-weekly bortezomib dosing schedule","id":"OG010","title":"Twice-weekly Bortezomib Dosing Schedule"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Toxicity of Participants Receiving Bortezomib, Rituximab, Cyclophosphamide, and Prednisone for Treatment of Non-Hodgkin's Lymphoma","type":"SECONDARY","unitOfMeasure":"Participants"}